<DOC>
	<DOC>NCT00036192</DOC>
	<brief_summary>The purpose of the study is to assess the safety and efficacy of FK614 in type 2 diabetic subjects receiving sulfonylurea (SU) monotherapy.</brief_summary>
	<brief_title>Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea</brief_title>
	<detailed_description>This is a prospective randomized, double-blind, placebo controlled, parallel group, Phase 2 study. Subjects meeting selection criteria will be randomly assigned to receive 12 weeks twice daily (BID) dosing with FK614 or placebo. Enrollment for this study will be approximately 200 patients.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Inclusion Criteria Has history of type 2 diabetes mellitus for at least 1 year Has been taking current sulfonylurea (SU) for at least 3 months. Subjects currently taking metformin may be eligible to be switched. Has not received any oral antidiabetic medication other than an SU or taken regularly prescribed insulin for at least 3 months Exclusion Criteria Has type 1 diabetes mellitus Has uncontrolled hypertension, i.e., systolic BP &gt;170 or diastolic BP &gt; 95 mm Hg. History of congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>